The findings, which were presented virtually in the 2020 ASCO Virtual Scientific Program, included the association between treatment with hydroxychloroquine plus azithromycin and increased risk of death.
Gabrielle Ientile, Assistant Editor
Although several therapeutic agents have been evaluated for the treatment of COVID-19, none have yet shown to be effective.
Filgotinib achieved all primary end points of the phase 2b/3 study in patients with moderate-to-severe ulcerative colitis.
The US Department of Health & Human Services partners with Phlow Corporation team to prevent drug shortages during the current pandemic and in future public health emergencies.
Approximately 20% to 30% of men with metastatic castration-resistant prostate cancer have HRR gene mutation.
Monitoring and controlling heart disease may be crucial in supporting cognitive health later in life.
Atezolizumab demonstrated a significant overall survival benefit in individuals with high PD-L1 expression compared with chemotherapy.
The US Department of Health & Human Services has left it up to state health departments to decide how to distribute remdesivir to hospitals.
Rucaparib is the first PARP inhibitor that has been approved in a prostate cancer setting.
A presentation from the 2020 PQA Annual Meeting examined how employers can engage in improving quality of care for those dependent on opioids.